Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069800 | 0.89 | HRH3 (0.55) | HRH3KDM4EALDH1A1SMN1; SMN2RET | |
| SCHEMBL22030561 | 0.86 | HRH3 (0.56) | HRH3KDM4EALDH1A1SMN1; SMN2RET | |
| SCHEMBL20148614 | 0.85 | HRH3 (0.52) | HRH3KDM4EALDH1A1SMN1; SMN2RET | |
| SCHEMBL9671156 | 0.71 | KDM4E (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL3583420 | 0.70 | HRH3 (1.00) | HRH3 | |
| SCHEMBL15033035 | 0.69 | HRH3 (0.71) | HRH3ALDH1A1UTS2R | |
| SCHEMBL13375741 | 0.68 | HRH3 (0.70) | HRH3ALDH1A1UTS2R | |
| SCHEMBL12359378 | 0.68 | HRH3 (0.73) | HRH3KDM4EALDH1A1SMN1; SMN2LSS | |
| SCHEMBL13374361 | 0.68 | HRH3 (0.68) | HRH3ALDH1A1UTS2R | |
| SCHEMBL110784 | 0.67 | KEAP1 (0.83) | HRH3KDM4EALDH1A1SMN1; SMN2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | HRH3 1148/4885KDM4E 889/4885ALDH1A1 2868/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1148/4885KDM4E 889/4885ALDH1A1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.